Application of exosome CD155 as hepatocellular carcinoma treatment target

By blocking CD155 or its receptor TIGIT in exosomes, it restores NK cell activity, and solves the problem of low response rate of hepatocellular carcinoma against PD-L1/PD-1 treatment to provide A new treatment plan for hepatocellular carcinoma has been improved.

CN118903423APending Publication Date: 2024-11-08THE FIRST AFFILIATED HOSPITAL OF WANNAN MEDICAL COLLEGE (YIJISHAN HOSPITAL OF WANNAN MEDICAL COLLEGE)
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202410947203.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In the prior art, the response rate of hepatocellular carcinoma against PD-L1/PD-1 is low, and the lack of effective exploration of immune checkpoint molecules in exosomes has led to limited treatment options for hepatocellular carcinoma.

Method used

The CD155 molecule carried in the exosomes is used as a therapeutic target for hepatocellular carcinoma, and by blocking CD155 or its receptor TIGIT, the killing activity of NK cells is restored, thereby improving the therapeutic effect.

Benefits of technology

By blocking CD155 or its receptor in exosomes, significantly restoring the killing ability of NK cells, a new hepatocellular carcinoma treatment scheme is provided, enhancing the effectiveness of immunotherapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903423A_ABST
    Figure CN118903423A_ABST
Patent Text Reader

Abstract

The invention discloses an application of an exosome CD155 as a hepatocellular carcinoma treatment target, and the killing activity of NK cells can be recovered by directly blocking the expression of the CD155 in the exosome or blocking a drug of a targeted exosome CD155 receptor. The invention discloses a novel immune checkpoint molecule existing in exosome, namely exosome CD155, the exosome CD155 is located in human serum and combined with a receptor to reduce NK activity, and the exosome CD155 can serve as a hepatocellular carcinoma treatment target. The killing ability of NK-92MI cells can be recovered to a certain extent by directly blocking CD155 secreted in the exosome or using a drug for blocking a targeted exosome CD155 receptor.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of therapeutic targets for hepatocellular carcinoma, and in particular to an application of exosome CD155 as a therapeutic target for hepatocellular carcinoma. Background Art

[0002] Since liver cancer usually has no obvious symptoms in its early stages, it can easily be delayed to the late stages. The mortality rate of liver cancer is extremely high, especially when diagnosed in the late stages. There are relatively few treatment options, making it difficult to reduce the mortality rate of liver cancer.

[0003] Exosomes are extracellular vesicles (EVs) with a diameter of about 30 to 200 nanometers secreted by cells. They have diagnostic value and the possibility of being used as therapeutic carriers, and have become a hot area of ​​biomedical research. In recent years, a number of articles have focused on studies related to the involvement of tumor cell-derived exosomes in immune escape by carrying immune checkpoints. For example, in 2018, Chen's team published a paper in Nature stating that metastatic melanoma releases high levels of exosomal PD-L1, thereby inhibiting the function of CD8+T cells and promoting tumor growth. In 2024, Annalen et al. reported in the journal J Extracell Vesicles that high levels of PD-L1 expression in extracellular vesicles can respond well to immunotherapy, and proposed that the positive level of PD-L1 in plasma can be used as a new predictive and prognostic indicator for immunotherapy.

[0004] However, only 10%-30% of patients respond to anti-PD-L1 / PD-1 treatment, and it is difficult for PD-L1 / PD-1 treatment to produce positive effects in prostate cancer and liver cancer. Therefore, how to further explore the immune checkpoint molecules present in exosomes to provide new options for immunotherapy has become a hot issue. Summary of the invention

[0005] The purpose of the present invention is to provide an application of exosome CD155 as a therapeutic target for hepatocellular carcinoma, so as to solve the technical problem of how to further explore the immune checkpoint molecules present in exosomes in the prior art.

[0006] In order to solve the above technical problems, the present invention specifically provides the following technical solutions:

[0007] The present invention provides a therapeutic target for hepatocellular carcinoma, including exosome CD155, wherein the exosome CD155 is a CD155 molecule carried by human serum exosomes.

[0008] The present invention also provides the use of exosome CD155 as a therapeutic target for hepatocellular carcinoma.

[0009] As a preferred embodiment of the present invention, the exosome CD155 is located in human serum, and the exosome CD155 can inhibit NK cell activation. At the same time, the exosome CD155 can inhibit the secretion of IFN-γ, TNF-α and Granzyme B of NK-92MI cells, thereby reducing the killing ability of NK-92MI cells.

[0010] As a preferred embodiment of the present invention, directly blocking the expression of CD155 in exosomes or blocking drugs that target exosome CD155 receptors can restore the killing activity of NK cells.

[0011] As a preferred embodiment of the present invention, the drug targeting the exosome CD155 receptor includes an anti-TIGIT antibody

[0012] The present invention also discloses a method for detecting hepatocellular carcinoma typing, comprising the following steps:

[0013] Exosome particles were extracted from the patient's serum, and the expression of specific antigens CD63 and Alix on the surface of exosome particles was detected;

[0014] According to the results of Elisa and flow cytometry, the amount of CD155 contained in exosome particles was positively correlated with the degree of hepatocellular carcinoma proliferation.

[0015] Exosomal CD155 can inhibit NK cell activation. At the same time, exosomal CD155 can inhibit the secretion of IFN-γ, TNF-α and Granzyme B in NK-92MI cells, thereby reducing the killing ability of NK-92MI cells.

[0016] Compared with the prior art, the present invention has the following beneficial effects:

[0017] The present invention discloses a novel immune checkpoint molecule present in exosomes, namely, exosome CD155. Exosome CD155 is located in human serum and binds to receptors to reduce NK activity. Exosome CD155 can be used as a therapeutic target for hepatocellular carcinoma. By directly blocking CD155 secreted in exosomes or using drugs that block targeted exosome CD155 receptors, the killing ability of NK-92MI cells can be restored to a certain extent. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] In order to more clearly illustrate the implementation methods of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for the implementation methods or the description of the prior art. Obviously, the drawings in the following description are only exemplary, and for ordinary technicians in this field, other implementation drawings can be derived from the provided drawings without creative work.

[0019] Figure 1 The present invention provides a schematic flow chart of the steps of separation and purification of serum exosomes shown in Example 1;

[0020] Figure 2 The present invention provides an electron micrograph of the exosomes shown in Example 1;

[0021] Figure 3 The present invention provides a partially enlarged electron microscope image of the exosome and its double-layer membrane structure shown in Example 1;

[0022] Figure 4 The present invention provides a diameter size diagram of exosomes identified by NanoSight NS300 particle tracking analyzer as shown in Example 1;

[0023] Figure 5 The present invention provides a Western blot analysis of exosomes using anti-human CD63 antibody and ALIX antibody as shown in Example 1 (using anti-human GAPDH antibody to detect GAPDH expression as a control);

[0024] Figure 6 The present invention provides a statistical graph of the exosome content in 100 μl of serum from hepatocellular carcinoma patients and healthy subjects extracted by the BCA method exosome detection kit shown in Example 1;

[0025] Figure 7 The present invention provides a graph showing the results of Western blot analysis of proteins expressed in serum exosomes of healthy and hepatocellular carcinoma patients using monoclonal anti-human CD155 antibody and TSG101 antibody as shown in Example 1;

[0026] Figure 8 The present invention provides a statistical graph of the expression level of HCC / HC serum exosome CD155 analyzed by flow cytometry as shown in Example 1;

[0027] Fig. 9 The present invention provides the sCD155 expression level diagram of hepatocellular carcinoma patients and healthy controls shown in Example 2;

[0028] Fig.10 The present invention provides the eCD155 expression level diagram of hepatocellular carcinoma patients and healthy controls shown in Example 2;

[0029] Fig.11 The present invention provides a graph of sCD155 expression levels in hepatocellular carcinoma patients of different genders as shown in Example 2;

[0030] Fig.12 The present invention provides a graph of eCD155 expression levels in hepatocellular carcinoma patients of different genders as shown in Example 2;

[0031] Fig.13The present invention provides a graph of sCD155 expression levels in hepatocellular carcinoma patients of different ages as shown in Example 2;

[0032] Fig.14 The present invention provides a graph of eCD155 expression levels in hepatocellular carcinoma patients of different ages as shown in Example 2;

[0033] Fig.15 The present invention provides a statistical graph showing the effect of exosomes from patients with hepatocellular carcinoma on the proliferation of NK-92MI cells as shown in Example 3 (cell mortality rate measured by LDH kit);

[0034] Fig.16 The present invention provides a statistical graph of the effect of exosomes from patients with hepatocellular carcinoma on the proliferation of NK-92MI cells as shown in Example 3 (cell viability is measured by CCK8 kit);

[0035] Fig.17 The present invention provides a statistical graph of the results of co-incubation of exosomes from healthy subjects and HCC patients, and LDH detection of the ability of NK-92MI cells to kill K562 (E:T=10:1) cells as shown in Example 3;

[0036] Fig.18 The present invention provides a statistical graph of the results of measuring Gramzy B by flow cytometry after the NK92-MI cells as shown in Example 3 were co-incubated with exosomes derived from HCC serum or HC serum exosomes;

[0037] Fig.19 The present invention provides a statistical graph of the results of ELISA determination of TNF-α and IFN-γ levels after co-incubation of NK92-MI with exosomes from HCC serum or HC serum exosomes as shown in Example 3;

[0038] Fig. 20 Provided is a statistical graph of the change results of the LDH detection of the ability of NK-92MI cells to kill K562 (E:T=10:1) cells as shown in Example 4 of the present invention;

[0039] Fig.21 The present invention provides a statistical graph of the results of ELISA determination of TNF-α and IFN-γ levels shown in Example 4;

[0040] Fig. 22 The present invention provides a statistical graph of the results of measuring the level of Gramzy B by flow cytometry as shown in Example 4;

[0041] Fig.23 The present invention provides an expression level diagram of sCD155 in HBsAg+ and HBsAg- HCC patients in stage I+II as shown in Application Example 1;

[0042] Fig.24The present invention provides an expression level diagram of eCD155 in HBsAg+ and HBsAg-HCC patients in stage I+II as shown in Application Example 1;

[0043] Fig.25 The present invention provides the expression level diagram of sCD155 in HBsAg+ and HBsAg-HCC patients in stage III+IV as shown in Application Example 1;

[0044] Fig.26 The present invention provides an expression level diagram of eCD155 in HBsAg+ and HBsAg-HCC patients in stage III+IV as shown in Application Example 1;

[0045] Fig. 27 The present invention provides the expression level diagram of sCD155 in AFP+ and AFP- HCC patients in stage I+II as shown in Application Example 2;

[0046] Fig.28 The present invention provides an expression level diagram of eCD155 in AFP+ and AFP- HCC patients in stage I+II as shown in Application Example 2;

[0047] Fig.29 The present invention provides the expression level diagram of sCD155 in AFP-L3+ and AFP-L3- HCC patients in stage I+II as shown in Application Example 2;

[0048] Fig.30 The present invention provides an expression level diagram of eCD155 in AFP-L3+ and AFP-L3- HCC patients in stage I+II as shown in Application Example 2;

[0049] Fig.31 The present invention provides the expression level diagram of sCD155 in AFP+ and AFP- HCC patients in stage III+IV as shown in Application Example 2;

[0050] Fig.32 The present invention provides an expression level diagram of eCD155 in AFP+ and AFP- HCC patients in stage III+IV as shown in Application Example 2;

[0051] Fig.33 The present invention provides the expression level diagram of sCD155 in AFP-L3+ and AFP-L3- HCC patients in stage III+IV as shown in Application Example 2;

[0052] Fig.34 The present invention provides the expression level diagram of eCD155 in AFP-L3+ and AFP-L3- HCC patients in stage III+IV as shown in Example 2;

[0053] Fig.35The present invention provides an analysis chart (I+II+III+IV) of serum sCD155 and eCD155 levels of hepatocellular carcinoma patients at different stages of hepatocellular carcinoma as shown in Application Example 3;

[0054] Fig.36 The present invention provides analysis diagrams (I+II, III+IV) of serum sCD155 and eCD155 levels of hepatocellular carcinoma patients at different stages as shown in Application Example 3. DETAILED DESCRIPTION

[0055] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0056] The examples are as follows:

[0057] Example 1: Verification of the presence of CD155 in exosomes:

[0058] 1. Isolation and purification of serum exosomes

[0059] (1) Peripheral blood samples from healthy subjects and HCC patients were collected from Wuhu Hospital (samples were stored at -20°C during collection);

[0060] (2) After taking out the sample, slowly dissolve it in a constant temperature water bath. After the sample returns to liquid state, immediately conduct the experiment;

[0061] (3) Ultracentrifuge the serum sample at 2000 × g for 20 min at 37°C, aspirate the supernatant, and retain the precipitate.

[0062] (4) Centrifuge the supernatant at 10,000 × g for 20 min and re-pipet the supernatant;

[0063] (5) Use an exosome purification kit for purification, add 0.2 times the total volume of the sample serum exosome extraction reagent, mix by inversion, incubate at 4°C for 2 hours, centrifuge at 1500×g for 15 minutes, discard the supernatant, centrifuge at 1500×g for 5 minutes, discard the supernatant, add 100 ml 1×PBS to resuspend the exosomes at the bottom, and use the sample for experiments or store it in a 4°C refrigerator for short-term storage, or in a -20°C refrigerator for long-term storage (the specific process is as follows Figure 1 shown).

[0064] 2. Electron microscopy observation

[0065] (1) Take 100 μl of 50 μg / ml exosome sample and fix it on a copper grid with paraformaldehyde at room temperature for 15 min;

[0066] (2) 2% phosphotungstic acid staining for 2 min;

[0067] (3) Incubate the exosome sample under an incandescent lamp for 10 min;

[0068] (4) Adjust the acceleration voltage of the transmission electron microscope, observe the sample and take pictures.

[0069] 3. Particle size analysis

[0070] (1) Clean the sample pool with deionized water;

[0071] (2) The instrument was calibrated with polystyrene microspheres (100 nm);

[0072] (3) Wash the sample pool with 1X PBS buffer (Biological Industries, Israel);

[0073] (4) The sample was diluted with 1X PBS buffer, the exosome concentration was controlled at 50 μg / ml, and the sample was injected for detection.

[0074] 4. Western blot

[0075] (1) Add lysis buffer to cells: dilute PMSF 1:100 to prepare premixed lysis buffer, add the premixed buffer to each well, and lyse on a shaker on ice for 30 min;

[0076] (2) Use a pipette to blow and scrape the cells in each well, aspirate them into a 1.5 mL EP tube, and centrifuge at 4°C, 15,000 g, for 15 min;

[0077] (3) Pipette the supernatant into a new EP tube, add 5× loading buffer (diluted to 1×), incubate at 100°C for 10 min, and store at -80°C for subsequent testing;

[0078] (4) Prepare gel: prepare 10% separation gel and 5% concentration gel, add appropriate 1× electrophoresis buffer to the electrophoresis tank, load 20 μL protein per well, and add protein markers at both ends;

[0079] (5) Gel running: voltage 80 V. When the sample reaches the separation gel, adjust to 120 V and stop electrophoresis according to the position of bromophenol blue and the size of the target protein.

[0080] (6) Transfer: Soak the PVDF membrane in an anhydrous methanol bath to activate it. Soak the sponge pad, filter membrane and transfer clip in pre-cooled transfer solution. Place the cut gel on the black side of the transfer clip. Place the PVDF membrane flat on the gel (cut corners to distinguish). Expel excess bubbles. Clamp the transfer clip and place it in the transfer tank. Fill it with transfer solution. Place on ice and transfer at 300 mA for 90 min.

[0081] 5. Dilution of standards and samples

[0082] The dilution process and dilution ratio were carried out as described in Table 1.

[0083] Table 1 Dilution of standard

[0084]

[0085] For samples with test concentration, take 5 times the standard dose and re-check.

[0086] (1) Add 100 μL of the standard sample to the first column of the 96-well ELISA plate of the kit according to the sample number, and make duplicate wells for the standard sample in the second column. Add 100 μL of the exosome sample to be tested to each of the remaining wells. Place in a 37°C cell culture incubator for 80 min.

[0087] (3) Discard the liquid in the wells and add an equal amount of washing solution to each well along the well wall. Shake gently for 20-30 seconds, then discard the liquid in the wells and blot dry with absorbent paper. Repeat three times.

[0088] (4) Add 100 μL of avidin-HRP to each well, shake gently to mix, and incubate in a 37°C cell culture incubator for 50 min.

[0089] (5) Discard the liquid in the wells and add an equal amount of washing solution to each well along the well wall. Shake gently for 20-30 seconds, then discard the liquid in the wells and dry with absorbent paper. Repeat three times.

[0090] (6) Add 90 μL of TMB to each well, shake gently, and incubate in a 37°C cell culture incubator in the dark for 10 min.

[0091] (7) Remove the ELISA plate and quickly add 50 μL of stop solution to each well along the well wall. Use an ELISA reader to read the OD value of each well at a wavelength of 450 nm.

[0092] 6. BCA quantitative detection of exosome concentration

[0093] First, completely dissolve the protein standard, take 15μL of protein standard and dilute it to 150μL with PBS to a final concentration of 0.5mg / mL, add 0, 1, 2, 4, 8, 12, 16, 20μL of the standard to the standard wells of the 96-well plate, add PBS to make up to 20μL, set up two sub-wells for each standard, add 5μL of exosomes to the sample well of the 96-well plate, and add PBS to make up to 20μL. According to the number of samples, prepare an appropriate amount of BCA working solution by adding 50 volumes of BCA reagent A and 1 volume of BCA reagent B (50:1), mix thoroughly, add 200μL of BCA working solution to each well, place at 37℃ for 30min, and measure the absorbance at 562nm with an enzyme reader. Draw a standard curve according to the concentration of the standard and the corresponding OD value, and substitute the OD value of the exosome to be tested into the standard curve to obtain the concentration of the exosomes.

[0094] 7. Detection of the presence of exosome CD155

[0095] 20ug of exosomes from the serum of hepatocellular carcinoma patients and healthy subjects were collected respectively, and the expression of CD155 was detected by Western blot, and the exosome marker molecule TSG101 was used as an internal reference.

[0096] 8. Detection of the expression of exosome CD155

[0097] The latex particles were co-incubated with exosomes for 24 h, and then stained with CD63 and CD155 related antibodies for flow cytometry experiments.

[0098] Result analysis:

[0099] (1) Extraction and identification of serum exosomes

[0100] First, serum was extracted from patients with hepatocellular carcinoma and healthy controls, and 100 μl of serum was taken to extract exosomes. The electron microscopy results were as follows: Figure 2 , Figure 3 As shown, the extracted exosomes have a typical single-layer membrane structure with a diameter of approximately 50-150 nm;

[0101] The results of the analysis using the NanoSight NS300 particle size analyzer are as follows: Figure 4 As shown, it was further verified that its diameter was between 50-150nm;

[0102] Western blot was used to detect exosome-related characteristic proteins CD63 and ALIX. The results are as follows Figure 5 As shown, the extracted exosomes expressed CD63 and ALIX, but did not express the intracellular reference protein GAPDH, while the control cells (PBMCs) did not express exosome characteristic proteins, but only expressed the intracellular reference protein GAPDH.

[0103] Therefore, the above results indicate that exosomes derived from the serum of healthy subjects and hepatocellular carcinoma patients were successfully extracted and separated.

[0104] (2) Quantitative analysis of serum exosomes

[0105] Protein quantification was performed by BCA assay, such as Figure 6 As shown, in 100 μl of serum, exosomes in the range of approximately 300±40.5 μg / ml were extracted from hepatocellular carcinoma patients, while exosomes in the range of approximately 230±40.5 μg / ml were extracted from healthy people, and the statistical analysis results showed that there was a significant difference between the two.

[0106] That is, the secretion of serum-derived exosomes from patients with hepatocellular carcinoma increases, which is related to their involvement in promoting the malignant progression of hepatocellular carcinoma.

[0107] (3) Exosomal CD155 is present in serum exosomes

[0108] Western blot detection Figure 7 As shown, the results showed that both serum exosomes of hepatocellular carcinoma patients and healthy subjects expressed CD155 molecules, and the expression level of exosome CD155 was significantly increased in hepatocellular carcinoma patients.

[0109] (4) Analysis of exosome CD155 expression

[0110] The results of flow cytometry experiments are shown in Figure 8 The results showed that the expression of CD155 on the membrane of serum exosomes in patients with hepatocellular carcinoma was significantly higher than that in healthy controls.

[0111] In summary, serum exosomes from both HCC patients and healthy controls expressed CD155, and exosomes from HCC patients expressed higher levels of CD155.

[0112] Example 2: Detection of the correlation between exosomes and CD155

[0113] Analysis of clinical characteristics of research subjects

[0114] To investigate the correlation between serum exosomal CD155 and liver cancer, 117 patients with hepatocellular carcinoma and 57 healthy controls were included in the study. The clinical characteristics of the subjects are shown in Table 2.

[0115] Table 2 Clinical characteristics of the subjects

[0116]

[0117]

[0118] The screening and clinical staging of the research subjects refer to the "Chinese Society of Clinical Oncology (CSCO) Primary Liver Cancer Diagnosis and Treatment Guidelines": patients with primary hepatocellular carcinoma who are hospitalized for the first time according to liver histopathology, imaging and laboratory tests; liver cancer stages I, II, III and IV are determined according to the number and size of liver tumors, vascular invasion, extrahepatic metastasis, Child-Pugh grade and physical condition. Exclusion criteria: patients with other malignant tumors or combined liver metastasis; those who have received immunomodulatory drug treatment in the past 6 months; patients with other serious autoimmune diseases and mental illnesses. Laboratory examinations of the subjects: serum HBV DNA was detected using fluorescent quantitative PCR (minimum detection limit 500 IU / mL); serum HBsAg levels (normal reference value: <0.05 IU / mL) and HBeAg levels (normal reference value: <1 S / CO) were detected using Roche automatic immunoassay analyzer; AFP (normal reference value: 0.89-8.78 ng / ml) and AFP-L3 (normal reference value: 0-1 ng / ml) were detected using Tesmi F4000 flow fluorescence luminescence method.

[0119] Values ​​are expressed as mean ± SD, median (P25, P75), number and / or percentage. HCC, hepatocellular carcinoma; HC, healthy control. P>0.05 for HCC and HC by chi-square test or t-test. M / F, male / female; (- / +), negative / positive. AFP, alpha-fetoprotein; AFP-L3, alpha-fetoprotein heterogeneity-L3.

[0120] 1. Analysis of eCD155 and sCD155 expression levels in hepatocellular carcinoma patients and healthy controls

[0121] Take 20ug of exosome sample and use ELISA eCD155 and sCD155 for quantitative detection. According to the ELISA test results, draw a standard curve to calculate the content of eCD155 and sCD155.

[0122] 2. Analysis of differences in sCD155 and eCD155 expression levels in hepatocellular carcinoma patients of different genders

[0123] The above ELISA method was used to detect 65 male and 12 female patients with hepatocellular carcinoma.

[0124] 3. Analysis of differences in sCD155 and eCD155 expression levels in patients with hepatocellular carcinoma of different ages

[0125] The above ELISA method was used to detect hepatocellular carcinoma patients ≤60 years old and hepatocellular carcinoma patients >60 years old.

[0126] Result analysis:

[0127] (1) High levels of eCD155 are present in serum exosomes from patients with hepatocellular carcinoma

[0128] like Fig. 9 , Fig.10 As shown in the figure, the levels of eCD155 and sCD155 derived from the serum of patients with hepatocellular carcinoma are higher than those of healthy controls. The experimental results of patients with hepatocellular carcinoma showed that CD155 exists in the serum exosomes of patients with hepatocellular carcinoma and the expression of CD155 is increased compared with healthy controls.

[0129] (2) eCD155 content is not related to the patient's gender

[0130] The statistical analysis results are as follows Fig.11 as well as Fig.12 As shown, there was no significant difference in the levels of sCD155 and eCD155 between patients with hepatocellular carcinoma of different genders (P>0.05).

[0131] (3) eCD155 content is not related to patient age

[0132] The statistical analysis results are as follows Fig.13 as well as Fig.14 As shown, there was no significant difference in the levels of sCD155 and eCD155 between the two groups of hepatocellular carcinoma patients of different age groups (P>0.05).

[0133] It can be seen from Examples 1 and 2 that the exosome CD155 (eCD155) provided by the present invention does exist. eCD155 is a protein carried in human serum exosomes and has a certain correlation with membrane CD155. High eCD155 expression can indicate to a certain extent that hepatocellular carcinoma occurs in the human body, and hepatocellular carcinoma promotes high expression of exosomes and eCD155.

[0134] At the same time, there are many methods for isolating exosomes. After multiple comparisons and screening of experimental conditions, the available separation methods include ultracentrifugation and sedimentation.

[0135] Although ultracentrifugation is the most commonly used method for isolating exosomes with high purity, it also has some disadvantages, such as only 6 samples can be processed at the same time in the same batch (rotor limitation) and the recovery rate is unstable. A large amount of materials need to be prepared in the early stage and the exosome yield is low. Most importantly, repeated centrifugation is likely to damage the exosome vesicles and reduce their quality. In addition, some soluble proteins can form clumps with exosomes and cause contamination. Therefore, conventional ultracentrifugation is excluded.

[0136] The present invention uses a precipitation method to separate exosomes. Further, the present invention preferably uses PEG incubation at 4°C and then precipitates and recovers exosomes by filtration or centrifugation, which is suitable for small volume samples such as serum. Further preferably, the present invention uses a kit precipitation method to separate serum exosomes from hepatocellular carcinoma patients and healthy people.

[0137] The function of eCD155 is verified by the following examples.

[0138] Example 3: Functional verification of eCD155

[0139] NK cell line (NK-92MI cells) and human chronic myeloid leukemia cells (K562) were selected.

[0140] 1. LDH detection killing test

[0141] (1) First, count the NK-92MI cells with a cell counting plate at 1×105 / mL, inoculate the cells into the culture plate, treat the NK-92MI cells with HD-exo and HP-exo (10ug / mL) for 24 hours, and finally add K562 cells and incubate with the NK-92MI cells for 6 hours. In the blocking experiment, NK-92MI cells were first treated with TIGIT Antibody for 24 hours;

[0142] (2) 2 h before detection, add 10 μL of lysis solution to the K562 control wells;

[0143] (3) Incubate the culture plate in an incubator for 4 hours;

[0144] (4) Centrifuge the 96-well plate at 500 g for 10 min, aspirate 50 μL of the supernatant into a new 96-well plate, add the colorimetric solution, and incubate in the dark for 10 min;

[0145] (5) Add 25uL of stop solution;

[0146] (6) Measure the absorbance at 450 nm using an enzyme-labeled instrument.

[0147] 2. CCK8 detection of cell proliferation

[0148] (1) Count the NK-92MI cells at 1×105 / mL using a cell counting plate, inoculate the cells into a culture plate, treat the NK-92MI cells with HD-exo and HP-exo (10 ug / mL) for 24 hours, and finally add K562 cells and incubate them with the NK-92MI cells for 6 hours.

[0149] (2) Add 10 μL of CCK solution to each well (be careful not to create bubbles in the wells)

[0150] (3) Incubate the culture plate in an incubator for 1-4 hours.

[0151] (4) Measure the absorbance at 450 nm using an enzyme-labeled instrument.

[0152] 3. Flow cytometry

[0153] 1×105 / mL NK-92MI cells were plated in each well of the well plate, and (20ug / mL TIGIT Antibody) was added for treatment for 24 hours. Then, 1×104 / mL K562 cells (target cells of NK-92MI) (E:T=10:1) were added. After 6 hours, the cells were taken out from the incubator, and NK cells were stimulated with PMA (50ng / mL) and ionomycin (1μg / mL). Golgi inhibitors were added at the same time, and the cells were added to a centrifuge tube after 4-6 hours.

[0154] (1) Incubate at 37°C and stain the cell surface using the corresponding flow cytometry antibodies.

[0155] (2) Centrifuge the sample at 2000 rpm for 5 min, discard the supernatant, retain the cell pellet, and wash once with PBS.

[0156] (3) Add 1 mL of 70% pre-cooled PBS to the centrifuge tube, mix well by pipetting, and fix in a 4°C refrigerator for 2 h. After centrifugation, discard the fixative and wash again with PBS.

[0157] (4) Intracellular cytokine staining was performed using PE-anti-TNFa and APC-anti-IFNγ at 4°C for 30 min.

[0158] (5) Flow cytometry detection, data analysis using FlowJo (TreeStar) software.

[0159] Result analysis:

[0160] (1) HCC-exo (exosomes) significantly inhibited the proliferation of NK-92MI cells

[0161] Fig.15 It was shown that after NK-92MI cells were treated with 10ug / ml HCC-exo and HC-exo for 24 hours, the LDH assay found that the amount of LDH released by NK-92MI cells treated with HCC-exo increased, indicating that the death of NK-92 cells increased; Fig.16 The CCK8 experiment showed that the cell viability of NK-92MI was significantly decreased. It can be seen that the CCK8 and LDH experiments revealed that HP-exo treatment would lead to a decrease in the proliferation ability of NK-92MI cells.

[0162] (2) HCC-exo causes abnormal NK-92MI cell killing function

[0163] The secretion of Gramzy B, IFN-γ, and TNF-α by HCC-exo-treated NK cells was detected by LDH, ELISA, and flow cytometry. The results of the LDH experiment showed that the mortality rate of K562 cells in the HP-exo-treated NK-92MI cell group was significantly reduced, indicating that the ability of HCC-exo-treated NK-92MI cells to kill K562 was significantly lower than that of the healthy group (p < 0.01, Fig.17 Flow cytometry revealed that Gramzy B ( Fig.18 In addition, ELISA experiments found that the secretion of IFN-γ and TNF-α in NK-92MI cells treated with HCC-exo was significantly reduced (p < 0.01, Fig.19 In summary, HCC-exo affects the killing function of NK-92MI cells, and the ability of NK cells to kill K562 cells is significantly reduced, which is mainly reflected in the reduction of cytokine secretion.

[0164] Example 4: Verification of the effect of eCD155 on NK-92MI cells

[0165] NK-92MI cells were treated with Anti-TIGIT antibody for 24 hours, and after blocking the TIGIT receptor of NK92-MI, they were co-incubated with K562 for 24 hours, and then the LDH killing experiment was performed.

[0166] Conclusion analysis:

[0167] (1) The effect of eCD155 on NK-92MI cells is TIGIT

[0168] LDH showed that after blocking TIGIT, the amount of LDH released by K562 increased, indicating that the ability of NK-92MI cells to kill K562 was enhanced ( Fig. 20 ); at the same time, ELISA detection of TNF-α and IFN-γ showed ( Fig.21 ), the secretion of TNF-α and IFN-γ increased significantly after blocking TIGIT; finally, flow cytometry showed that the secretion of Gramzy B also increased after blocking TIGIT ( Fig. 22 ).

[0169] It can be seen from Examples 3 and 4 that exosome CD155 inhibits NK cell activation, and exosome CD155 also inhibits the secretion of IFN-γ, TNF-α and Granzyme B in NK-92MI cells, reducing the killing ability of NK-92MI cells. Anti-TIGIT antibodies can partially restore the inhibitory effect of serum exosomes from hepatocellular carcinoma patients on NK-92MI cells.

[0170] Application example 1: The expression level of exosome CD155 is closely related to HBV-related HCC patients

[0171] The levels of sCD155 and eCD155 in peripheral blood serum of patients with stage I+II HBsAg-related HCC were detected respectively;

[0172] The levels of sCD155 and eCD155 in peripheral blood serum of patients with stage III+IV HBsAg-related HCC were detected.

[0173] The results are analyzed as follows:

[0174] See Fig.23 There was no significant difference in serum sCD155 levels between HBsAg(+) and HBsAg(-) stage I+II HCC patients;

[0175] See Fig.25 There was no significant difference in sCD155 levels between HBsAg(+) and HBsAg(-) stage III+IV HCC patients and the healthy control group.

[0176] But see Fig.24 The expression of eCD155 in HBsAg(+) stage I+II HCC patients was higher than that in HBsAg(-) stage I+II HCC patients. Fig.26 The eCD155 levels in both HBsAg(+) and HBsAg(-) stage III+IV HCC patients were significantly different from those in the healthy control group.

[0177] Depend on Fig.24 , Fig.26 It can be seen that the expression level of exosomal CD155 is closely related to HBV-related HCC patients. By detecting the expression level of exosomal CD155, it is possible to determine to a certain extent what stage of cancer the patient is in and whether it is related to HBV.

[0178] At the same time, Application Example 1 proves that exosomal CD155 is different from ordinary membrane CD155 or other CD155 and has different functions.

[0179] Application Example 2: The serum eCD155 level in early HCC patients is high and is not affected by the expression levels of AFP and / or AFP-L3

[0180] Figures 27 to 30 The levels of sCD155 and eCD155 in stage I+II HCC patients with different status of AFP or AFP-L3 were shown;

[0181] Figure 31 to Figure 34The levels of sCD155 and eCD155 in stage III+IV HCC patients with different status of AFP or AFP-L3 are shown.

[0182] The analysis is as follows:

[0183] result Fig.28 and Fig.30 As shown, the levels of serum exosomal CD155 in AFP(+) or (-) HCC patients and AFP-L3(+) or (-) HCC patients in stage I+II were significantly higher than those in HC patients.

[0184] result Fig.32 and 34 As shown, the serum exosomal CD155 levels of AFP(+) or (-) HCC patients and AFP-L3(+) or (-) HCC patients in stage I+II were significantly higher than those in HC patients;

[0185] like Fig.31 As shown in Figure 2, there was no significant change in serum sCD155 levels between the AFP(+), AFP(-) and healthy groups; Fig.33 As shown, there was no significant change in serum sCD155 levels between the AFP-L3(+), AFP-L3(-) and healthy groups.

[0186] Therefore, the results showed that the serum eCD155 levels in early HCC patients were higher regardless of AFP / AFP-L3(+) or AFP / AFP-L3(-), and the detection of eCD155 in early HCC patients was not affected by the expression levels of AFP and / or AFP-L3.

[0187] By detecting the eCD155 content in patients, early HCC patients can be identified, facilitating early detection and treatment.

[0188] Application Example 3: eCD155 can determine different stages of liver cancer

[0189] The quantitative results of sCD155 and eCD155 in patients with different stages and healthy subjects were compared and analyzed. The specific results are shown in Fig.35 and Fig.36 .

[0190] Result analysis:

[0191] Compared with the HC group, the eCD155 content in HCC stage I, III, and IV was significantly increased (P < 0.01), suggesting that eCD155 is associated with tumor progression ( Fig.35 );

[0192] Compared with the HC group, there was no significant difference in sCD155 between patients with HCC stage II, III, and IV (P>0.05), but there was a significant difference in sCD155 between patients with HCC stage I (P<0.05) ( Fig.36 ).

[0193] It can be seen that Application Example 3 shows that eCD155, rather than sCD155, is closely related to the malignant progression of hepatocellular carcinoma. There are differences in the application between eCD155 and sCD155. At the same time, eCD155 can determine the stage of liver cancer to a certain extent, which is convenient for judging the stage type of liver cancer in patients through in vitro detection.

[0194] The exosome CD155 provided in this embodiment can be used as a therapeutic target for hepatocellular carcinoma. By directly blocking the CD155 secreted in the exosomes or using drugs that block the targeted exosome CD155 receptor, the killing ability of NK-92MI cells can be restored to a certain extent.

[0195] The above embodiments are only exemplary embodiments of the present application and are not intended to limit the present application. The protection scope of the present application is defined by the claims. Those skilled in the art may make various modifications or equivalent substitutions to the present application within the essence and protection scope of the present application, and such modifications or equivalent substitutions shall also be deemed to fall within the protection scope of the present application.

Claims

1. Application of exosomal CD155 as a therapeutic target for hepatocellular carcinoma.

2. The use according to claim 1, characterized in that: The exosomal CD155 is located in human serum; Wherein, the exosome CD155 can inhibit NK cell activation; The exosome CD155 can inhibit the secretion of IFN-γ, TNF-α and Granzyme B of NK-92MI cells, thereby reducing the killing ability of NK-92MI cells.

3. The use according to claim 1, characterized in that: The killing activity of NK cells can be restored by directly blocking the expression of CD155 in exosomes or blocking drugs that target the exosomal CD155 receptor.

4. The use according to claim 1, characterized in that: The drug targeting the exosomal CD155 receptor includes an anti-TIGIT antibody.

Citation Information

Patent Citations

  • Application of serum sCD155 as hepatocellular carcinoma biomarker

    CN117092341A